Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Myopathy due to Chronic Clevudine Therapy - A Case Report -

´ëÇѺ´¸®ÇÐȸÁö 2009³â 43±Ç 6È£ p.575 ~ 579
±èÁö¿µ, À±¿µ½Å, ¹Ú±â´ö, ±¸Çý¼ö,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁö¿µ ( Kim Jee-Young ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç

À±¿µ½Å ( Yoon Young-Shin ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç
¹Ú±â´ö ( Park Kee-Duk ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ ½Å°æ°úÇб³½Ç
±¸Çý¼ö ( Koo Hea-Soo ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


A 40-year-old man with chronic hepatitis B complained of progressive weakness of the proximal muscles and edema of both legs. He had been receiving long-term clevudine (nucleoside analogue reverse transcriptase inhibitor, NRTI) therapy for his hepatitis. The serum creatine kinase level was increased on the laboratory tests. His electromyography showed a generalized myopathic process. The muscle biopsy showed numerous ragged-red fibers, degenerating myofibers with variable sized cytoplasmic bodies, the prominence of type 1 fibers with type 2 fiber atrophy and an endomysial mononuclear cell infiltration. The electron microscopic examination revealed necrotic myofibers, including extremely dysmorphic mitochondria with extensive loss, blunting and focal clumping of the cristae and concentric cristae. Although clevudine is known to be a less cytotoxic agent among the various NRTIs, careful clinical attention should be paid to the patients who are receiving long-term clevudine therapy for the occurrence of myopathy.

Å°¿öµå

Clevudine;Mitochondrial Myopathies

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS